Search clinical trials for: Brexpiprazole (OPC-34712)

Total 946 results

Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia (VECTOR)

Acute Schizophrenia

Korea, Republic of, United States, Serbia, Ukraine, Romania, Poland, Canada, Latvia, Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg

Healthy Adult Male

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Trial of OPC-34712 in Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Multicenter, Open-label, Safety and Tolerability Study (STEP 210)

Schizophrenia

United States, Bulgaria, Philippines, Romania, Russian Federation, Serbia, Croatia, India, Korea, Republic of, Slovakia, Taiwan, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia (ZENITH)

Schizophrenia

Korea, Republic of, United States, Philippines, Malaysia, Croatia, Serbia, Russian Federation, Ukraine, Romania, Puerto Rico, Colombia, Turkey, Poland, Taiwan, Canada, Latvia, Slovakia, Mexico, Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

Schizophrenia | Psychiatric Disorders

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia (BEACON)

Acute Schizophrenia

United States, Philippines, Taiwan, Russian Federation, Croatia, Colombia, Mexico, Slovakia
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

France, United States, Bulgaria, Slovenia, United Kingdom, Russian Federation, Ukraine, Finland, Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (Anchor)

Irritability Associated With Autism Spectrum Disorder (ASD)

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

Spain, United States, Germany, Croatia, Serbia, Russian Federation, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Terminated

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects

Healthy Adult Male

Japan
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

ADHD | Conduct Disorder | Oppositional Defiant Disorder | Autism | Bipolar I Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.

Bipolar I Disorder | Acute Mania

United States, Serbia, Bulgaria, Croatia, Poland, Ukraine
Otsuka Pharmaceutical Development & Commercialization...

Completed

Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)

Borderline Personality Disorder

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Agitation Associated With Dementia of the Alzheimer's Type

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Canada Pharmaceutical Inc.; Lundbeck Canada Inc.

Completed

Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Major Depressive Disorder

Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Active, not recruiting

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Irritability Associated With Autism Spectrum Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial) (Pyxis)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, France, Poland, Canada, Slovakia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

Alzheimer Dementia | Agitation Associated With Alzheimer's Dementia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

Stress Disorders, Post-Traumatic

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Withdrawn

Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability

Major Depressive Disorder and Irritability

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) (Polaris)

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Russian Federation, Hungary, Romania, Ukraine, Canada, Germany
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity

Schizophrenia With Impulsivity

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Active, not recruiting

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (STEP-D222)

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder (STEP-A)

Attention Deficit Hyperactivity Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Poland, Serbia, Russian Federation, Germany, Canada, France
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Development & Commercialization, Inc.

Recruiting

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Acute Schizophrenia

Japan
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

Cardiac Edema (CHF)

Japan
Eye & ENT Hospital of Fudan University

Recruiting

An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma

Oropharynx Carcinoma

China
Otsuka Pharmaceutical Co., Ltd.

Withdrawn

A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia

Schizophrenia
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes Type 2

Japan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma (MM)

Japan
Kyowa Kirin Co., Ltd.

Completed

Along-term Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

Pain Due to Osteoporosis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Otsuka Pharmaceutical Co., Ltd.

Terminated

A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Otsuka Pharmaceutical Development & Commercialization...
Bill and Melinda Gates Foundation

Completed

A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis

Pulmonary TB

South Africa

Search clinical trials for: Brexpiprazole (OPC-34712)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations